Summary by Dr. Vera Hirsh
Lung cancer remains one of the most common cancers worldwide and a leading cause of cancer-related deaths, with an estimated 1.6 million new cases and nearly 1.4 million deaths annually. The majority of patients with non small cell lung cancer (NSCLC) will present with advanced stage disease at diagnosis. But even when diagnosed at an early stage, a large number of patients will eventually experience disease relapse with metastases. Five-year survival rate of lung cancer patients is only 15%. Furthermore, patients with advanced lung cancer may experience debilitating symptoms and toxicities related to their treatments, which can seriously effect their quality of life.